Unfractionated heparin

BivaLirudin versUS Heparin in Extracorporeal Membrane Oxygenation

Intranasal Heparin Treatment to Reduce Transmission Among Household Contacts of COVID 19 Positive Adults and Children

Biological and Clinical Measurements Following Systemic Leakage When a Citrate or Heparin Lock is Used

Citrate Versus Heparin for the Lock of Non-tunneled Hemodialysis Catheters in Patients Hospitalised in ICU

Impact of Pre-Hospital Heparin Loading in STEMI Patients for Primary PCI: The HELP-PCI 2 Trial

Use of Bivalirudin for Anticoagulation in Patients With Extracorporeal Membrane Oxygenation

Bivalirudin With Prolonged Full Dose Infusion Versus Heparin Alone During Emergency PCI

Inhaled Heparin for Hospitalised COVID-19 Patients

Pretreatment With Unfractionated Heparin for ST Elevation Myocardial Infarction

Bivalirudin with Prolonged Infusion During PCI Versus Heparin After Fibrinolytic Therapy

Comparing Anticoagulation Strategies Using UFH, Argatroban and LMWH for ECMO Support

Safety and Feasibility of Argatroban As Anticoagulant in Adults with ECMO

The Effect of Exercise on Pharmacodynamics and Pharmacokinetics of a Single Dose of Unfractionated Heparin

Comparison of Nafamostat and Unfractionated Heparin in RRT for Sepsis Associated AKI

Safety and Efficacy of Argatroban Applicated in Anticoagulation of V-V ECMO

Inhaled Heparin for Hospitalised Patients With Coronavirus Disease 2019 (COVID-19)

Standard vs High Dose of Unfractionated Heparin in the Incidence of Radial Artery Occlusion (DEFINITION) Trial.

Comparison of Biocompatibility of Plasmapheresis Procedures With Citrate and Heparin Anticoagulation

Unfractionated Heparin in COVID-19 and Non-COVID-19 Patients

Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial)